Skip to main content
Log in

Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Chronic pseudomonal bronchopulmonary infections in cystic fibrosis patients are frequently controlled with inhaled antibiotics. Dry-powder inhalable antibiotics are an attractive alternative to nebulized medications. We produced and evaluated microparticles composed of dipalmitoylphosphatidylcholine, albumin, and lactose as a model system for intrapulmonary delivery of ceftazidime, ciprofloxacin, and several combinations of the two, none of which is presently available for inhalation. Microparticles containing one or both antibiotics were prepared by spray-drying. Their Anderson cascade impactor deposition profiles showed 10–30% fine particle fractions of the nominal dose. Microparticles containing varying amounts of each antibiotic showed statistically different deposition profiles. Aerodynamics and deposition of microparticles co-encapsulating both antibiotics were similar to those of single-drug microparticles with the same proportion of ciprofloxacin alone. The antipseudomonal activities of microparticles co-encapsulating half of the 50% effective concentration (EC50) of both ceftazidime and ciprofloxacin (5 mg of particles containing 5% ceftazidime and 10% ciprofloxacin) were at least additive compared to particles containing the EC50 of each antibiotic separately (5 mg of particles containing 10% ceftazidime or 5 mg of particles containing 20% ciprofloxacin). Co-encapsulation of the antibiotics in microparticles ensures co-deposition at desired ratios, improves the particles’ aerodynamics and fine particle fraction, as compared to microparticles with equivalent amounts of ceftazidime alone, and achieves additive antipseudomonal activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. A. R. Penketh, A. Wise, M. B. Mearns, M. E. Hodson, and J. C. Batten. Cystic fibrosis in adolescents and adults. Thorax. 42(7):526–532 (1987).

    Article  PubMed  CAS  Google Scholar 

  2. M. I. Gomez, and A. Prince. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr Opin Pharmacol (2007).

  3. M. E. Hodson, and C. G. Gallagher. New clinical evidence from the European tobramycin trial in cystic fibrosis. J. Cyst. Fibros. 1(Suppl 2):199–202 (2002).

    Article  PubMed  CAS  Google Scholar 

  4. B. W. Ramsey, M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, K. M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1):23–30 (1999).

    Article  PubMed  CAS  Google Scholar 

  5. M. E. Hodson. Antibiotic treatment. Aerosol therapy. Chest. 94(2 Suppl):156S–162S (1988).

    Article  PubMed  CAS  Google Scholar 

  6. P. W. Campbell 3rd, and L. Saiman. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest. 116(3):775–788 (1999).

    Article  PubMed  CAS  Google Scholar 

  7. L. Weathers, D. Riggs, M. Santeiro, and R. E. Weibley. Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 9(3):220–221 (1990).

    Article  PubMed  CAS  Google Scholar 

  8. L. Máiz, R. Cantón, N. Mir, F. Baquero, and H. Escobar. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatric. Pulmonology. 26(4):287–289 (1998).

    Article  PubMed  Google Scholar 

  9. J. D. Gradon, E. H. Wu, and L. I. Lutwick. Aerosolized vancomycin therapy facilitating nursing home placement. Ann. Pharmacother. 26(2):209–210 (1992).

    PubMed  CAS  Google Scholar 

  10. B. Laube. Aerosol delivery systems. In G. Loughlin, and H. Eigen (eds.), Respiratory Disease in Children: Diagnosis and Management, Williams and Wilkins, Baltimore, MD, 1994, pp. 721–729.

    Google Scholar 

  11. R. S. Bernard, and L. L. Cohen. Increasing adherence to cystic fibrosis treatment: a systematic review of behavioral techniques. Pediatr. Pulmonol. 37(1):8–16 (2004).

    Article  PubMed  Google Scholar 

  12. M. A. Wall, A. B. Terry, J. Eisenberg, M. McNamara, and R. Cohen. Inhaled antibiotics in cystic fibrosis. Lancet. 1(8337):1325 (1983).

    Article  PubMed  CAS  Google Scholar 

  13. R. L. Elmore, M. E. Contois, J. Kelly, A. Noe, and A. Poirier. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin. Ther. 18(2):246–255 (1996).

    Article  PubMed  CAS  Google Scholar 

  14. C. G. Prober, P. D. Walson, and J. Jones. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics. 106(6):E89 (2000).

    Article  PubMed  CAS  Google Scholar 

  15. C. Bosquillon, C. Lombry, V. Preat, and R. Vanbever. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release. 70(3):329–339 (2001).

    Article  PubMed  CAS  Google Scholar 

  16. C. Bosquillon, P. G. Rouxhet, F. Ahimou, D. Simon, C. Culot, V. Preat, and R. Vanbever. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release. 99(3):357–367 (2004).

    Article  PubMed  CAS  Google Scholar 

  17. R. E. Dostal, J. P. Seale, and B. J. Yan. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis. Med. J. Aust. 156(1):20–24 (1992).

    PubMed  CAS  Google Scholar 

  18. J. Watkins, J. Francis, and J. A. Kuzemko. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa? Scand. J. Gastroenterol. Suppl. 143:81–85 (1988).

    Article  PubMed  CAS  Google Scholar 

  19. S. M. Cheer, J. Waugh, and S. Noble. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 63(22):2501–2520 (2003).

    Article  PubMed  CAS  Google Scholar 

  20. A. L. Smith, B. W. Ramsey, D. L. Hedges, B. Hack, J. Williams-Warren, A. Weber, E. J. Gore, and G. J. Redding. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmonol. 7(4):265–271 (1989).

    Article  PubMed  CAS  Google Scholar 

  21. J. L. Burns, J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5):1190–1196 (1999).

    Article  PubMed  CAS  Google Scholar 

  22. D. N. Fish, M. K. Choi, and R. Jung. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J. Antimicrob. Chemother. 50(6):1045–1049 (2002).

    Article  PubMed  CAS  Google Scholar 

  23. S. L. Pendland, C. R. Messick, and R. Jung. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 42(1):75–78 (2002).

    Article  PubMed  CAS  Google Scholar 

  24. D. A. Edwards, A. Ben-Jebria, and R. Langer. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 85(2):379–385 (1998).

    PubMed  CAS  Google Scholar 

  25. D. S. Kohane, M. Lipp, R. C. Kinney, N. Lotan, and R. Langer. Sciatic nerve blockade with lipid–protein–sugar particles containing bupivacaine. Pharm. Res. 17(10):1243–1249 (2000).

    Article  PubMed  CAS  Google Scholar 

  26. R. Vanbever, J. D. Mintzes, J. Wang, J. Nice, D. Chen, R. Batycky, R. Langer, and D. A. Edwards. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. V16(11):1735 (1999).

    Article  Google Scholar 

  27. D. S. Kohane, S. E. Smith, D. N. Louis, G. Colombo, P. Ghoroghchian, N. G. M. Hunfeld, C. B. Berde, and R. Langer. Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain. 104(1,2):415–421 (2003).

    Article  PubMed  CAS  Google Scholar 

  28. J. Castillo, J. Curley, J. Hotz, M. Uezono, J. Tigner, M. Chasin, R. Wilder, R. Langer, and C. Berde. Glucocorticoids prolong rat sciatic nerve blockade in vivo from bupivacaine microspheres. Anesthesiology. 85(5):1157–1166 (1996).

    Article  PubMed  CAS  Google Scholar 

  29. G. Colombo, R. Padera, R. Langer, and D. Kohane. Prolonged duration local anesthesia with lipid–protein–sugar particles containing bupivacaine and dexamethasone. J. Biomed. Mater. Res. A. 75(2):458–464 (2005).

    PubMed  Google Scholar 

  30. J. P. Mitchell, and M. W. Nagel. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J. Aerosol. Med. 16(4):341–377 (2003).

    Article  PubMed  CAS  Google Scholar 

  31. J. M. Goldman, S. M. Bayston, S. O’Connor, and R. E. Meigh. Inhaled micronised gentamicin powder: a new delivery system. Thorax. 45(12):939–940 (1990).

    PubMed  CAS  Google Scholar 

  32. N. R. Crowther Labiris, A. M. Holbrook, H. Chrystyn, S. M. Macleod, and M. T. Newhouse. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am. J. Respir. Crit. Care Med. 160(5 Pt 1):1711–1716 (1999).

    PubMed  CAS  Google Scholar 

  33. M. T. Newhouse, P. H. Hirst, S. P. Duddu, Y. H. Walter, T. E. Tarara, A. R. Clark, and J. G. Weers. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 124(1):360–366 (2003).

    Article  PubMed  CAS  Google Scholar 

  34. H. Adi, P. M. Young, H. K. Chan, P. Stewart, H. Agus, and D. Traini. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci. (2007).

  35. Gentamicin. Micromedex® Healthcare Series. Thomson Micromedex

  36. Ciprofloxacin. Micromedex® Healthcare Series. Thomson Micromedex

  37. Ceftazidime. Micromedex® Healthcare Series. Thomson Micromedex

Download references

ACKNOWLEDGMENT

We would like to express our gratitude to Henry Dorkin, MD for helpful insights. This work was supported by Cystic Fibrosis Foundation Research and Clinical Fellowship grant (TSIFAN02B0) to MDT and NIH GM073626 to DSK.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel S. Kohane.

Additional information

Michael D. Tsifansky and Yoon Yeo contributed equally.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsifansky, M.D., Yeo, Y., Evgenov, O.V. et al. Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics. AAPS J 10, 254–260 (2008). https://doi.org/10.1208/s12248-008-9033-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-008-9033-8

KEY WORDS

Navigation